Tositumomab

Jump to: navigation, search
Tositumomab?
Therapeutic monoclonal antibody
Source o
Target CD20
Identifiers
CAS number 192391-48-3
ATC code V10XA53 (sequential regimen with 131I form)
PubChem  ?
DrugBank DB00081
Chemical data
Formula C6416H9874N1688O1987S44 
Mol. mass 143859.7 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tositumomab was a drug that was approved for the treatment of relapsed or chemotherapy/rituxan-refractory Non-Hodgkin lymphoma in 2003.[1] It was sold in the U.S. and Canada under the trade name Bexxar. Sale of the drug was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.[2][3]

This drug combination was developed by Corixa which was purchased by GlaxoSmithKline) in 2005.[4]

References


Linked-in.jpg